Vitae Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VTAE)

$21.00 0.00 (0.00 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$21.00
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market Capitalization$605.66 million
P/E Ratio-10.94
Dividend YieldN/A
BetaN/A

About Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Receive VTAE News and Ratings via Email

Sign-up to receive the latest news and ratings for VTAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:VTAE
CUSIPN/A
Phone+1-215-4612000

Debt

Debt-to-Equity RatioN/A
Current Ratio12.83%
Quick Ratio12.83%

Price-To-Earnings

Trailing P/E Ratio-10.9375
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.92)
Net IncomeN/A
Net Margins-318,350.20%
Return on Equity-53.70%
Return on Assets-49.85%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Vitae Pharmaceuticals (NASDAQ:VTAE) Frequently Asked Questions

What is Vitae Pharmaceuticals' stock symbol?

Vitae Pharmaceuticals trades on the NASDAQ under the ticker symbol "VTAE."

How were Vitae Pharmaceuticals' earnings last quarter?

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) released its quarterly earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative return on equity of 53.70% and a negative net margin of 318,350.20%. The business's revenue for the quarter was down 98.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.45) EPS. View Vitae Pharmaceuticals' Earnings History.

Who are some of Vitae Pharmaceuticals' key competitors?

How do I buy Vitae Pharmaceuticals stock?

Shares of Vitae Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vitae Pharmaceuticals' stock price today?

One share of Vitae Pharmaceuticals stock can currently be purchased for approximately $21.00.

How big of a company is Vitae Pharmaceuticals?

Vitae Pharmaceuticals has a market capitalization of $605.66 million. Vitae Pharmaceuticals employs 56 workers across the globe.

How can I contact Vitae Pharmaceuticals?

Vitae Pharmaceuticals' mailing address is 502 W Office Center Dr, FORT WASHINGTON, PA 19034-3215, United States. The biotechnology company can be reached via phone at +1-215-4612000.


MarketBeat Community Rating for Vitae Pharmaceuticals (VTAE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about Vitae Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vitae Pharmaceuticals (NASDAQ:VTAE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AHold
Consensus Rating Score: N/AN/AN/A2.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$21.67
Price Target Upside: N/AN/AN/A3.92% upside

Vitae Pharmaceuticals (NASDAQ:VTAE) Consensus Price Target History

Price Target History for Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals (NASDAQ:VTAE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
9/15/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$17.00 -> $21.00N/AView Rating Details
9/14/2016WedbushDowngradeOutperform -> Neutral$21.00 -> $23.00N/AView Rating Details
9/14/2016Stifel NicolausDowngradeBuy -> Hold$21.00N/AView Rating Details
9/11/2016Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Vitae Pharmaceuticals (NASDAQ:VTAE) Earnings History and Estimates Chart

Earnings by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals (NASDAQ VTAE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2($0.41)($0.36)$0.05 millionViewListenView Earnings Details
5/10/2016Q1($0.51)($0.44)$0.09 million$0.05 millionViewListenView Earnings Details
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details
5/12/2015Q115($0.33)($0.47)$0.16 million$0.15 millionViewListenView Earnings Details
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vitae Pharmaceuticals (NASDAQ:VTAE) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Vitae Pharmaceuticals (NASDAQ VTAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 72.58%
Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals (NASDAQ VTAE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2016Adage Capital Partners Gp, L.LMajor ShareholderSell1,025,000$20.85$21,371,250.00View SEC Filing  
9/14/2016Jeffrey S HatfieldCEOSell50,000$20.81$1,040,500.00244,996View SEC Filing  
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.601,935View SEC Filing  
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00293,897View SEC Filing  
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vitae Pharmaceuticals (NASDAQ VTAE) News Headlines

Source:
DateHeadline
Contrasting Cesca Therapeutics (KOOL) and Vitae Pharmaceuticals (VTAE)Contrasting Cesca Therapeutics (KOOL) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - January 4 at 9:56 AM
Vitae Pharmaceuticals (VTAE) versus Peregrine Pharmaceuticals (PPHM) Critical SurveyVitae Pharmaceuticals (VTAE) versus Peregrine Pharmaceuticals (PPHM) Critical Survey
www.americanbankingnews.com - December 27 at 7:30 PM
Head to Head Review: Cardiome Pharma (CRME) & Vitae Pharmaceuticals (VTAE)Head to Head Review: Cardiome Pharma (CRME) & Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - December 18 at 11:50 AM
Vitae Pharmaceuticals (VTAE) & Kadmon (KDMN) Head to Head ReviewVitae Pharmaceuticals (VTAE) & Kadmon (KDMN) Head to Head Review
www.americanbankingnews.com - November 25 at 3:20 PM
Head-To-Head Survey: Vitae Pharmaceuticals (VTAE) & Alexion Pharmaceuticals (ALXN)Head-To-Head Survey: Vitae Pharmaceuticals (VTAE) & Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - November 21 at 1:34 PM
Vitae Pharmaceuticals (VTAE) vs. MediWound (MDWD) Head to Head ComparisonVitae Pharmaceuticals (VTAE) vs. MediWound (MDWD) Head to Head Comparison
www.americanbankingnews.com - October 26 at 1:16 AM
Head to Head Review: Kamada (KMDA) vs. Vitae Pharmaceuticals (VTAE)Head to Head Review: Kamada (KMDA) vs. Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - October 14 at 6:20 PM
Comparing Anika Therapeutics (ANIK) & Vitae Pharmaceuticals (VTAE)Comparing Anika Therapeutics (ANIK) & Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - October 3 at 8:22 PM
Vitae Pharmaceuticals (VTAE) and Its Peers Critical ReviewVitae Pharmaceuticals (VTAE) and Its Peers Critical Review
www.americanbankingnews.com - September 20 at 4:12 PM
Reviewing VIVUS (VVUS) and Vitae Pharmaceuticals (VTAE)Reviewing VIVUS (VVUS) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - September 19 at 12:48 AM
Head to Head Comparison: Vitae Pharmaceuticals (VTAE) & Its RivalsHead to Head Comparison: Vitae Pharmaceuticals (VTAE) & Its Rivals
www.americanbankingnews.com - September 18 at 4:30 PM
Contrasting Onconova Therapeutics (ONTX) and Vitae Pharmaceuticals (VTAE)Contrasting Onconova Therapeutics (ONTX) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - September 11 at 8:36 PM
Financial Analysis: Vitae Pharmaceuticals (VTAE) versus Vericel Corporation (VCEL)Financial Analysis: Vitae Pharmaceuticals (VTAE) versus Vericel Corporation (VCEL)
www.americanbankingnews.com - August 14 at 4:31 PM
Critical Survey: Catalyst Biosciences (CBIO) and Vitae Pharmaceuticals (VTAE)Critical Survey: Catalyst Biosciences (CBIO) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - August 7 at 10:08 PM
Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw InterestAmgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
finance.yahoo.com - July 30 at 7:17 AM
6 Best Performing Drug Stocks of September6 Best Performing Drug Stocks of September
finance.yahoo.com - July 30 at 7:17 AM
Allergan - Waiting For Pipeline CatalystsAllergan - Waiting For Pipeline Catalysts
seekingalpha.com - June 29 at 3:22 PM
Allergan Shifts Strategy to Focus on Growth - TheStreet.comAllergan Shifts Strategy to Focus on Growth - TheStreet.com
www.thestreet.com - January 11 at 3:32 PM
Allergan to Veer Toward Accretive M&A - TheStreet.comAllergan to Veer Toward Accretive M&A - TheStreet.com
www.thestreet.com - January 10 at 9:06 PM
Allergan: You Cant Be Negative On This OneAllergan: You Can't Be Negative On This One
seekingalpha.com - December 21 at 3:31 PM
4 Reasons To Buy Allergan4 Reasons To Buy Allergan
seekingalpha.com - November 28 at 10:38 AM
$690M done deal: Allergan completes Vitae acquisition$690M done deal: Allergan completes Vitae acquisition
www.bizjournals.com - November 11 at 8:02 PM
VITAE PHARMACEUTICALS, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquisitVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - October 25 at 8:07 PM
Allergan, Vitae Pharma Announce Expiration Of HSR Waiting Period - Quick FactsAllergan, Vitae Pharma Announce Expiration Of HSR Waiting Period - Quick Facts
www.rttnews.com - October 17 at 7:53 PM
VITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces ... - PR Newswire (press release)VITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces ... - PR Newswire (press release)
www.prnewswire.com - September 25 at 6:58 AM
Allergans Vitae buy could spark more interest in KadmonAllergan's Vitae buy could spark more interest in Kadmon
www.thestreet.com - September 23 at 6:49 AM
Allergans Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - BenzingaAllergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - Benzinga
www.benzinga.com - September 21 at 11:53 AM

SEC Filings

Vitae Pharmaceuticals (NASDAQ:VTAE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vitae Pharmaceuticals (NASDAQ:VTAE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vitae Pharmaceuticals (NASDAQ VTAE) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.